- Trubion
= Trubion =
Trubion is a publicly held
biopharmaceutical company that is focused on creating a pipeline of protein-based therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. Trubion was established in 1999 in the State of Washington as an early stage development company, and was later reincorporated in October 2002 in the State of Delaware.In December 2005, Trubion entered into a collaborative agreement with Wyeth [http://www.wyeth.com/cbd/history/casestudies/trubion] for the development and worldwide commercialization of
CD20 -directed therapeutics. The agreement also includes the development and worldwide commercialization of certain other product candidates directed to targets other than CD20. The research portion of Trubion’s contract with Wyeth currently extends through December 22, 2009.Product Pipeline
Technology
Trubion’s current product development efforts are focused on three technology pillars: SMIP™ protein therapeutics, SCORPION™ protein therapeutics and TRU-ADhanCe™ potency enhancing technology for immunopharmaceuticals.
SMIP, or
small modular immunopharmaceutical , therapeutics are single chain polypeptides comprising one binding domain, one hinge domain and one effector domain designed in an effort to meet predetermined therapeutic specifications for specific diseases. SMIP therapeutics are mono-specific (they recognize and attach to single antigen targets and initiate biological activity). Trubion is working on SMIP drug candidates that target validated antigens with the same specificity and predictable biological activity asmAbs .SCORPION protein therapeutics are also single chain polypeptides comprised of functional domains from naturally occurring proteins. The difference between SMIP and SCORPION technologies is that SCORPION compounds are multi-specific therapeutics that are capable of targeting two or more antigens simultaneously.
TRU-ADhanCe potency enhancing technology is designed to enhance the potency of existing therapies that work through Fc-directed or antibody-directed cellular cytotoxicity, or
ADCC . TRU-ADhanCe technology can be applied late in development to established manufacturing lines and generate candidates with increased ADCC and longer in-vivo half lives.
Wikimedia Foundation. 2010.
